Compare XE & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XE | RDY |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.9B |
| IPO Year | 2026 | 2001 |
| Metric | XE | RDY |
|---|---|---|
| Price | $19.04 | $12.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.90 |
| AVG Volume (30 Days) | ★ 5.6M | 2.9M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.29 | $11.36 |
| 52 Week High | $23.99 | $15.67 |
| Indicator | XE | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 44.06 |
| Support Level | $13.56 | $11.47 |
| Resistance Level | $20.18 | $12.58 |
| Average True Range (ATR) | 2.01 | 0.20 |
| MACD | -0.14 | 0.06 |
| Stochastic Oscillator | 23.78 | 59.50 |
X-Energy Inc is a leading developer of advanced SMR and fuel technology for clean energy generation. It is seeking to redefine the nuclear energy industry through its flagship product, the Xe-100, an advanced small modular HTGR designed to generate up to 80 megawatts of electric power and/or up to 200 megawatts of thermal output, depending on the configuration. X-energy's simple and intrinsically safe advanced SMR designs, like the Xe-100, significantly expand the applications and markets for nuclear technology with enhanced safety, lower cost and faster construction timelines when compared with conventional nuclear energy sources and broader use cases when compared with other SMRs.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.